AISAP Cardio vs EchoNext
AI Verdict
Choose AISAP Cardio if…
Choose AISAP Cardio if you need an AI-powered point-of-care ultrasound solution for rapid, comprehensive cardiac diagnostic assessments directly at the bedside. It's ideal for clinicians in cardiology, emergency medicine, and primary care who require immediate, AI-assisted interpretation of cardiac ultrasounds to detect structural heart disease and heart failure, assess valvular pathologies, and measure key cardiac parameters, especially in settings like clinics, skilled nursing facilities, and mobile screening units.
View AISAP Cardio →Choose EchoNext if…
Choose EchoNext if you need an AI tool to screen for hidden structural heart disease, including heart failure, valve disease, and pulmonary hypertension, using standard ECGs. This is particularly useful for broad access screening in various clinical settings, from major hospitals to community practices, as it can identify patients at high risk who should proceed to an echocardiogram for definitive diagnosis.
View EchoNext →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | AISAP Cardio | EchoNext |
|---|---|---|
| Pricing | Not publicly available | Starts at $600/month |
| Deployment | Cloud-based SaaS platform | Available through the OpenEvidence clinical decision support platform. |
| BAA Available | Unknown | Yes AI-estimated |
| FDA Status | 1 AI-estimated | Yes AI-estimated |
| HIPAA | Unknown | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
AISAP CardioAISAP Cardio is designed for point-of-care use, enabling rapid assessments at the bedside and integrating seamlessly into existing clinical workflows, EHR/EMR, and PACS systems. This focus on immediate, integrated use by a wide range of clinicians, including non-cardiologists, suggests a highly user-friendly design. EchoNext, while also aiming for broad access, is deployed through a clinical decision support platform, which may introduce an additional layer of interaction.
Clinical Value
EchoNextEchoNext demonstrates superior accuracy in detecting structural heart disease from ECGs, outperforming cardiologists even when aided by AI. It also has a broader range of detected conditions from a widely available and inexpensive test. AISAP Cardio shows high sensitivity and specificity for significant major valve diseases and improved clinician accuracy in interpreting POCUS, but EchoNext's ability to 'see' what cardiologists can't from a routine ECG offers a significant new screening paradigm.
Pricing & Value
EchoNextEchoNext provides transparent tiered pricing starting at $600/month, with discounts and add-ons clearly outlined. AISAP Cardio's pricing is not publicly available, requiring direct contact for information. This transparency from EchoNext allows potential users to better assess the financial investment and overall value proposition upfront.
Enterprise Readiness
TieBoth tools demonstrate strong enterprise readiness. AISAP Cardio is a cloud-based SaaS platform that is vendor-agnostic and integrates with existing EHR/EMR and PACS systems. EchoNext is HIPAA compliant, has a BAA, and is deployed through the OpenEvidence clinical decision support platform, which is used by a large number of US physicians. Both are FDA-cleared, indicating adherence to regulatory standards for medical devices.
Innovation
EchoNextEchoNext represents a significant innovation by enabling the detection of hidden structural heart disease from standard ECGs, a test that traditionally couldn't provide such insights. This transforms a widely available, inexpensive test into a powerful screening tool. While AISAP Cardio offers advanced AI for POCUS interpretation, EchoNext's ability to extract novel diagnostic information from a routine ECG is a more disruptive innovation in early disease detection.
Support & Docs
TieNeither product's provided information or web search results offer extensive details on specific support channels, documentation availability, or training programs. Both companies likely offer standard support for their medical device software, but without explicit information, it is difficult to differentiate them on this dimension.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | AISAP Cardio | EchoNext |
|---|---|---|
| Name | AISAP Cardio | EchoNext |
| Company | Aisap | Pathway Labs |
| Description | FDA-cleared, AI-powered point-of-care ultrasound (POCUS) software platform that provides rapid, comprehensive cardiac diagnostic assessments and measurements, enabling early detection of structural heart disease and heart failure at the bedside. | FDA-cleared AI tool from Pathway Labs that analyzes standard ECGs to detect hidden structural heart disease, including heart failure, valve disease, and pulmonary hypertension. |
| Key Features | AI-powered interpretation for early cardiac disease detection; Comprehensive cardiac ultrasound software package; Automated generation of analyses, interpretations, and reports; Assessment of valvular pathologies (mitral, tricuspid, aortic regurgitation, aortic stenosis); Measurement of Left Ventricle Ejection Fraction (LVEF); Measurement of right and left ventricular dimensions, atrial areas, ascending aorta diameter, and IVC diameter; Vendor-agnostic and scalable solution; Integration with existing clinical workflows, EHR/EMR, and PACS | AI-powered ECG analysis; Detection of hidden structural heart disease; Identifies heart failure risk; Screens for valve disease; Detects pulmonary hypertension indicators; Utilizes standard 12-lead ECGs; FDA-cleared technology; Non-invasive diagnostic support |
| Specialties | Cardiology, Emergency Medicine, Radiology | Cardiology, Family Medicine, Hospital Medicine, Internal Medicine |
Videos
Demos, reviews, and walkthroughs featuring AISAP Cardio and EchoNext.